Patents Examined by Jennifer Dunston
  • Patent number: 10337065
    Abstract: In one embodiment, the present invention relates to a method for optimizing cell-type specific protein expression. In another embodiment, the present invention relates to a method for creating a tRNA profile of a cell.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 2, 2019
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Sohail Tavazoie, Hani Goodarzi
  • Patent number: 10329595
    Abstract: The current invention reports a promoter that has the nucleic acid sequence of SEQ ID NO: 02 or SEQ ID NO: 03 which is a human CMV major immediate-early (hCMV-MIE) promoter/enhancer with C to G point mutation at position ?41 and/or ?179 relative to the transcription start site. This new promoter is especially useful for the production of polypeptides at large scale as it shows reduced promoter silencing and improved polypeptide production.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: June 25, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Goepfert, Benjamin Moritz
  • Patent number: 10324085
    Abstract: Described herein is a bioluminescence resonance energy transfer (BRET) based system and method to monitor ternary complex formation in real-time in live cells with high sensitivity and accuracy. This system transfers energy simultaneously between a luciferase donor and intermediate and terminal acceptors, appropriately chosen to also enable transfer from the intermediate to terminal acceptor while minimizing contaminating signals. The system may also be adapted for quaternary complex detection by including a protein complementation assay (PCA) component. The system is broadly applicable to the detection of any protein ternary/quaternary complex such as those involving nuclear receptors, GPCRs, Receptor Tyrosine Kinase (RTKs), multimeric enzymes or structural proteins.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 18, 2019
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: David Cotnoir-White, Sylvie Mader, Étienne Gagnon, Michel Bouvier
  • Patent number: 10266851
    Abstract: Compositions and methods for using programmable DNA binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: April 23, 2019
    Assignee: Sigma-Aldrich Co. LLC
    Inventor: Fuqiang Chen
  • Patent number: 10267804
    Abstract: Provided herein is a method of using transposition to improve methods of sequencing RNA molecules. Provided herein is a method of tagging nucleic acid duplexes, such as DNA:RNA duplexes or DNA:DNA duplexes. The method includes the steps of providing a transposase and a transposon composition, providing one or more nucleic acid duplexes immobilized on a support, and contacting the transposase and transposon composition with the one or more nucleic acid duplexes under conditions wherein the one or more nucleic acid duplexes and transposon composition undergo a transposition reaction to produce one or more tagged nucleic acid duplexes, wherein the transposon composition comprises a double stranded nucleic acid molecule comprising a transferred strand and a non-transferred strand.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 23, 2019
    Assignee: ILLUMINA CAMBRIDGE LIMITED
    Inventors: Niall Anthony Gormley, Louise Fraser, Paula Kokko-Gonzales
  • Patent number: 10246705
    Abstract: Artificial transposon sequences having code tags and target nucleic acids containing such sequences. Methods for making artificial transposons and for using their properties to analyze target nucleic acids.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: April 2, 2019
    Assignee: Ilumina, Inc.
    Inventors: Frank J. Steemers, Kevin L. Gunderson, Thomas Royce, Natasha Pignatelli, Igor Goryshin, Nicholas Caruccio
  • Patent number: 10227654
    Abstract: The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: March 12, 2019
    Assignee: The Johns Hopkins University
    Inventors: William G. Nelson, Srinivasan Yegnasubramanian, Xiaohui Lin, Traci J. Speed, Zachery Reichert
  • Patent number: 10221422
    Abstract: The present invention provides methods for light-dependent gene regulation using a light-responsive DNA-binding protein. Also provided are related nucleic acid molecules, and protein molecules, such as those encoding or comprising the light-responsive DNA-binding protein or DNA-binding sites recognizing the light-responsive DNA-binding protein. Kits using the present light-dependent gene regulation system are further provided by the present invention.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: March 5, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kevin H. Gardner, Laura B. Motta-Mena, Brian D. Zotowski
  • Patent number: 10208304
    Abstract: Described herein is a method that generally includes infecting a host cell with a rescue adenovirus, wherein the rescue adenovirus genome comprises a loxP site and encodes at least one marker, and wherein the host cell comprises a library of polynucleotides that complement the adenovirus genome marker and encode a detectable polypeptide; incubating the infected host cell under conditions effective to permit recombination between the adenovirus genome and one or more of the library polynucleotides and the production of recombinant adenovirus particles comprising at least on detectable polypeptide; and detecting the at least one detectable polypeptide. Also described are adenovirus libraries constructed using such a method.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: February 19, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Masato Yamamoto, Yoshiaki Miura
  • Patent number: 10196650
    Abstract: The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: February 5, 2019
    Assignee: JNC CORPORATION
    Inventor: Satoshi Inouye
  • Patent number: 10188748
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilized by sequence modifications and optimized for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilization and translational efficiency of modified mRNA of the invention.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: January 29, 2019
    Assignee: CureVac AG
    Inventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
  • Patent number: 10179932
    Abstract: Methods of labelling one or more subcellular components (e.g., an organelle and/or subcellular region) in vivo are provided. Methods of labelling a protein in vivo are provided. Methods of determining a nucleic acid sequence in situ are also provided.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 15, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Je-Hyuk Lee, Evan R. Daugharthy
  • Patent number: 10175256
    Abstract: The invention relates to compositions and methods for utilizing lysophosphatidylcholine scaffolds. The compositions and methods can be used for LPC-mediated delivery of fatty acids and other molecules; to screen and identify fatty acid formulations for parenteral nutrition; and for live animal organ imaging, among other uses. The invention also provides compositions and methods for utilizing mutations and polymorphisms in human Mfsd2a as markers for neurological deficits.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: January 8, 2019
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: David Lawrence Silver, Nam Long Nguyen, Robert Zahler
  • Patent number: 10174379
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation and related to suppressing thymic cancer, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, immunogenic and apoptotic genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: January 8, 2019
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
  • Patent number: 10155938
    Abstract: A composition used in targeted mutagenesis is provided, which includes a first expression cassette comprising a nucleotide sequence which encodes a CAS9 endonuclease; a second expression cassette comprising a nucleotide sequence which encodes a guide RNA sequence, wherein the guide RNA sequence is complementary to a target genome nucleotide sequence in a cell; and a third expression cassette comprising a nucleotide sequence which encodes a Trex2 exonuclease (Trex2) gene. The first, second, and third expression cassettes may be a part or a portion of one or more expression vectors.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 18, 2018
    Assignee: CITY OF HOPE
    Inventors: Jeremy M. Stark, Diana Yanez
  • Patent number: 10144927
    Abstract: The present invention provides methods for conducting screens using nucleic acid elements (e.g., interfering RNAs) to confidently identify hit genetic elements. The present invention further comprises constructing vectors that contain two or more nucleic acid elements to knock down all pairwise combinations of the hit genetic elements identified from the screen. Following quantitation of the single and double-knockdown phenotypes, genetic interactions between all gene pairs can be calculated. Genes can then be clustered according to the similarity of the pattern of their interactions with all of the other genes to obtain a genetic interaction map, which can advantageously be used to predict functional associations between genes and identify drug targets for therapy such as combination cancer therapy.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: December 4, 2018
    Assignee: The Regents of the University of California
    Inventors: Martin Kampmann, Michael Bassik, Jonathan Weissman
  • Patent number: 10138493
    Abstract: Embodiments disclosed herein provide artificial expression systems comprising the zinc-finger containing transcription factors and engineered promoters to modulate expression of genes of interest. Engineered zinc-finger transcription factors that interact with engineered promoters constitute synthetic and regulatable expression systems which facilitate the modulation of gene expression as desired.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: November 27, 2018
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE GENERAL HOSPITAL CORPORATION
    Inventors: Ahmad S. Khalil, Divya Israni, Minhee Park, J. Keith Joung, Jeffry D. Sander
  • Patent number: 10106799
    Abstract: The present invention relates to nucleic acid constructs comprising selectable marker genes in a multicistronic transcription unit for use in the generation and selection of eukaryotic host cells for expression of a gene product of interest. For increased stringency of selection, the coding sequence of the selectable marker may be directed preceded by a relatively short functional open reading frame to reduce the efficiency of translation of the selectable marker, and/or the amino acid sequence of the selectable marker may comprise one or more mutations that reduce the level of resistance provide by the mutated marker as compared to its wild type counterpart. The invention further relates to methods for generating eukaryotic host cells for expression of a gene product of interest, wherein these nucleic acid constructs are used, and to methods for producing a gene product of interest wherein thus generated host cells are applied.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: October 23, 2018
    Assignee: CELLAGENICS B.V.
    Inventors: Arie Pieter Otte, Henricus Johannes Maria Van Blokland, John Antonius Verhees
  • Patent number: 10087489
    Abstract: Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: October 2, 2018
    Assignee: The University of Notre Dame
    Inventors: Steven Buechler, Amanda B. Hummon
  • Patent number: 10066231
    Abstract: Materials and methods are provided which allowed for increased expression of a transfected gene of interest in a recombinant host cell.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 4, 2018
    Assignee: CMC ICOS BIOLOGICS, INC.
    Inventor: Howard Robert Grahame Clarke